Silexion (SLXN) Net earnings per share growth forecast for next year

Corporate company logo of Silexion Therapeutics (SLXN)

The closed loop of RNA engineering and clinic quotas in the US and Israel limit patient reach, which determines the cost dynamics for Silexion Therapeutics Corp (SLXN). The projected growth in the company's net profit demonstrates these complexities, where the value of 60.30 expresses the metric level. The absence of revenue due to the pre-commercial status of R&D and geopolitical barriers in biomaterial logistics make the generation of a stable cash flow virtually unattainable.

Silexion (SLXN): Net earnings per share growth forecast for next year from 08/17/2024 to 11/18/2026

Summary analytical data breakdowns for Silexion Therapeutics Corp (SLXN)

- share price and consensus valuation forecast:
Fundamental company analysis:Silexion Therapeutics Corp.
Finished products of Silexion

For Silexion Therapeutics Corp (SLXN), which develops personalized RNA cancer therapies, the forward earnings per share (EPS) growth forecast reflects the consensus valuation of the future profitability of its innovative developments. This indicator measures the expected net income dynamics, filtering out market noise and allowing investors to assess the fundamental capitalization potential of Silexion Therapeutics Corp (SLXN) through the lens of the probable commercial success of its gene technologies.

Competitor analysis for Silexion Therapeutics Corp

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology Inc.)|BYSI (BeyondSpring) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (Lixte Biotechnology Holdings, Inc.)|Citius Pharmaceuticals, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year canfite.com (CANF)|Net earnings per share growth forecast for next year aprea.com|KZIA: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)